Brief: Cartesian Therapeutics' Cash & Cash Equivalents Expected To Support Planned Operations Into 2026
08/01/2024 14:16
Jan 8 (Reuters) - Cartesian Therapeutics Inc RNAC.O :
* CARTESIAN THERAPEUTICS : ABOUT $118 MILLION PRO FORMA
CASH &
CASH EQUIVALENTS AS OF DEC31, 2023, EXPECTED TO SUPPORT PLANNED
OPERATIONS INTO 2H OF 2026
* CARTESIAN THERAPEUTICS : CLINICAL PIPELINE EXPANDED
FOLLOWING
RECENT IND CLEARANCE FOR DESCARTES-15, A NEXT-GENERATION MRNA
CAR-T PRODUCT CANDIDATE
* CARTESIAN THERAPEUTICS : PHASE 2 STUDY OF DESCARTES-08 IN
SYSTEMIC LUPUS ERYTHEMATOSUS EXPECTED TO INITIATE IN 1H24
Source text for Eikon: ID:nGNX8nDG3c
Further company coverage: RNAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cartesian Therapeutics
See all newsBrief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview